Business Wire

Worldwide Clinical Trials And Trialbee Partner To Boost Recruitment, Optimize Timelines, And Reduce Time To Market

Share

Worldwide Clinical Trials, Inc., (Worldwide) the industry’s leading global, midsized, full-service contract research organization (CRO), and Trialbee, a patient matching and enrollment company, today announced they are teaming up to streamline patient recruitment for clinical trials globally.

The two fast-growing organizations will combine global trial infrastructure, therapeutic expertise, and proven recruitment capabilities with innovative technology, real-world data, and nurse call center qualification. The partnership will improve trial sponsors’ ability to match and enroll eligible clinical trial participants globally.

“This collaboration benefits the industry by optimizing clinical development timelines and benefits patients through faster time to market for needed medications,” said Matt Walz, CEO, Trialbee. “By combining the global development expertise of Worldwide Clinical Trials with our global patient matching and enrollment platforms, this partnership will lower costs and speed clinical trial timelines with innovative patient matching and enrollment capabilities.”

Increasingly complex clinical study designs and the growing demand for larger and more diverse patient pools have made it harder to find and retain eligible clinical trial participants. These are expensive problems, especially for Worldwide’s target market. Among small and midsized pharma and biotechs:

  • Over 50% of regulated clinical trials fail to meet planned enrollment targets, risking study data quality and development timelines.1
  • Trends in protocol designs have contributed to a major decline in patient recruitment and retention across disease conditions, resulting in longer clinical trial cycle times. 57% of participants in Phase II and 36% of participants in Phase III trials across all therapeutic areas fail screening and randomization.2

Together, Worldwide and Trialbee will tailor services to bring down the cost of drug development by matching, enrolling, and engaging motivated, qualified clinical trial participants who are representative of the diverse global population.

Small to midsized pharma and biotech sponsors rate Worldwide highly for its flexible approach and deep appreciation of the pathophysiological mechanisms, innovative clinical trial designs, operations rigor, and global scale needed to move the industry forward.

Through its new partnership, Worldwide’s customers will now have the additional benefit of Trialbee’s advanced data science to optimize protocol design and site selection and transform patient identification, enrollment, and engagement.

“Worldwide’s vision is to be the world’s best midsized CRO – with the focus, global scale, and scientific and medical expertise that small and midsized pharma and biotechs deserve in a development partner,” said Peter Benton, president and COO, Worldwide Clinical Trials. “Now, with our collaboration with Trialbee, we’re thrilled to offer them access to advanced data science. This, in turn, will help us transform patient recruitment, optimize clinical development timelines, and reduce the time to market.”

Trialbee Hive™ incorporates global access to real-world data and data science to match the most appropriate study participants while ensuring proper population representation. Once matched, interested patients are qualified by an online prequalification process followed by a video or phone-based interview through Trialbee’s nurse call center.

About Worldwide Clinical Trials

Worldwide Clinical Trials employs 2,000+ professionals around the world, with offices in North and South America, Eastern and Western Europe, Russia, and Asia-Pacific. Founded by physicians committed to advancing medical science, Worldwide is out to change how the world experiences CROs – in the best possible way. From early phase and bioanalytical sciences through late phase, post-approval, and real-world evidence, we provide world-class, full-service drug development services.

With infrastructure and talent spanning 60 countries, we execute predictable, successful studies with operational excellence across a range of therapeutic areas, including central nervous system, cardiovascular, metabolic, general medicine, oncology, and rare diseases. We never compromise on science or safety. We’re never satisfied with the status quo. We’re the Cure for the Common CRO. For more information, visit www.worldwide.com.

About Trialbee

Trialbee is the leading global data and technology platform for patient matching and enrollment in clinical trials. Trialbee Hive™ operationalizes real-world data (RWD) and applies data science to match patients globally. Our Candidate Manager platform simplifies the journey for matched patients to qualify and participate in clinical research. Partnering with sponsors, CROs, and virtual/decentralized sites and software providers, Trialbee is achieving patient enrollment goals and driving enhancements in diversity in clinical trial populations. We are the smartest way to match and enroll patients for your clinical trial. For more information, visit www.trialbee.com or contact us at solutions@trialbee.com.

Sources:

  1. Huang, G., Bull, J., McKee, K., Mahon, E., Harper, B., Roberts, J. (2018). Clinical trials recruitment planning: A proposed framework from the Clinical Trials Transformation Initiative. Contemporary Clinical Trials, Volume 66, 2018, Pages 74-79, ISSN 1551-7144, https://doi.org/10.1016/j.cct.2018.01.003.
  2. Cameron, D., Willoughby, C., Messer, D., Lux, M., Aitken, M., & Getz, K. (2020). Assessing Participation Burden in Clinical Trials: Introducing the Patient Friction Coefficient. Clinical Therapeutics. doi:10.1016/j.clinthera.2020.06.015

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Worldwide Clinical Trials
Sherri Stuart
VP, Global Corporate Communications
Sherri.Stuart@worldwide.com

Trialbee
Rosina Ferrante
Gregory FCA
rosina.ferrante@trialbee.com

About Business Wire

Business Wire
Business Wire



Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Kolmar Korea Wins Case Against Italian Cosmetics Maker Intercos for Suncare Technology Theft28.3.2024 14:00:00 CET | Press release

Kolmar Korea (KRX:161890), a Korean cosmetics ODM (Original Development Manufacturing) company, has announced its victory in a lawsuit against Intercos Korea, the Korean subsidiary of the Italian cosmetics maker, Intercos. Intercos was revealed to have misappropriated and profited from the key technology for suncare (sunscreen) products, originally developed by Kolmar Korea. Kolmar Korea had invested hundreds of billions of KRW in this technology. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240328015022/en/ Kolmar Korea wins the case against Italian cosmetics maker Intercos for stealing suncare technology (Kolmar Korea R&D Complex) (Photo: Kolmar Korea Holdings) Kolmar Korea took legal action for 'trade secret infringement' against its former employees who have leaked the technology and Intercos Korea, resulting in favorable rulings in both civil and criminal cases. The Korean courts ordered Intercos Korea to pay KRW 200

Tigo Energy Headquarters Receives 90kW of Optimized Solar from Long-Time Installer Partner28.3.2024 14:00:00 CET | Press release

Tigo Energy, Inc. (NASDAQ: TYGO), a leading provider of intelligent solar and energy software solutions, today announced the installation and commissioning of a rooftop solar system at its headquarters in California. The system was designed and deployed by Tigo installer partner, Laibach Solar, and has averaged 5% Reclaimed Energy since it was commissioned. Laibach Solar is an employee-owned solar installer in Northern California dedicated to combining high-quality components with unbeatable pricing. It has been a valued installation partner for Tigo since 2018. The installation now contributes to the growth of U.S. corporate solar adoption, which was 14% of the U.S. Solar Market as of 2022, according to the Solar Energy Industries Association. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240328503393/en/ The system was designed and deployed by Tigo installer partner Laibach Solar and has averaged 5% Reclaimed Energy since

Seoul Semiconductor Supplies WICOP to Front Headlamps of 2024 Genesis GV80, Leading Trend of Headlamps28.3.2024 14:00:00 CET | Press release

Seoul Semiconductor Co., Ltd. (KOSDAQ:046890), the world best-in-class technology in opto-semiconductors, is supplying and mass-producing “WICOP,” the world’s first high-power LEDs without wire, for the headlamps of Genesis GV80, a luxury SUV model by Hyundai Motor Group, which is one of the world’s top three automobile companies. The technology applies to all functions of the high-light, sophisticated headlamps introduced by GV80. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240328561793/en/ Headlamps of GV80, a luxury SUV of Genesis, with Seoul Semiconductor’s WICOP technology applied (Photo: Seoul Semiconductor Co., Ltd.) Seoul Semiconductor applied its new technology of Ultra-High Luminance “WICOP UHL” to the high and low beams of GV80, the two lines that symbolize Genesis vehicles. With its improved luminance by 200% compared to existing mass-produced WICOP products, WICOP UHL is attracting the attention of the automo

Crown Bioscience Announces New Preclinical and Translational Oncology Data Across Ten Poster Presentations at AACR 202428.3.2024 13:30:00 CET | Press release

Crown Bioscience, a global contract research organization (CRO) and a JSR Life Sciences company, will showcase significant contributions in preclinical and translational oncology research at the American Association for Cancer Research (AACR) 2024 meeting. Highlighting its latest research, the company will present ten posters covering a broad spectrum of data from the company's R&D program. The data presented will cover a range of innovative techniques in oncology and immuno-oncology drug discovery and development. Posters featured at AACR include: The in-depth Characterization of Acute Myeloid Leukemia Patient-Derived Xenograft (PDX) Models with Hotspot Gene Mutations for Therapeutic Evaluation. The development of an Integrated Pipeline for Immuno-Oncology Drug Testing, using patient-derived tumor organoids with a reconstituted tumor microenvironment and fresh ex vivo patient tissue cultures, aiming to enhance therapeutic evaluation and drug development efficiency with translational p

Philip Morris International Demonstrates Clear Progress Toward Its Purpose as It Releases 2023 Integrated Report28.3.2024 12:38:00 CET | Press release

Philip Morris International Inc. (PMI) (NYSE: PM) today releases its fifth annual Integrated Report, which outlines the company’s ongoing work to advance toward its 2025 Roadmap goals, with the primary focus on addressing the health impacts of the company’s products. The 2023 Integrated Report highlights PMI’s continued expansion of smoke-free alternatives in markets worldwide, as well as social and environmental programs deployed with and in parallel to these products—including the deployment of responsible marketing and sales practices and efforts to reduce post-consumer waste. Further, PMI reports its progress toward fostering an empowered and inclusive workplace, improving the quality of life of people in its supply chain, decarbonizing its operations and value chain, and preserving nature and biodiversity. “2023 was a year marked by unity, determination, and a continued commitment to our vision of a smoke-free future,” said Jacek Olczak, Chief Executive Officer of PMI. “As we enco

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
HiddenA line styled icon from Orion Icon Library.Eye